HER2-positive ovarian cancer means the tumor cells carry unusually high amounts of a growth-signal protein, the same marker long known from breast cancer. For years HER2 mattered little in ovarian cancer, but newer drugs that use it as a homing signal have changed that, so testing is now recommended for recurrent disease.1HER2Know. HER2-Positive Ovarian Cancer: Diagnosis and Treatment The label isn’t a simple yes or no, though, and how strongly the tumor carries HER2 shapes which options apply.
What HER2 Does and Which Ovarian Cancers Have It
HER2 is a protein that sits on the outer surface of cells and passes along signals that tell the cell to grow. When a cell has extra copies of the HER2 gene or a change in it, it makes too much of the protein.2PubMed Central. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer The growth signals then stay switched on, pushing tumor cells to multiply and spread.3PubMed Central. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer Ovarian HER2 has been studied far less than breast cancer HER2, so some answers are still being worked out.
How often it shows up depends on the type of ovarian cancer. Moderate or strong HER2 staining appears in about half of mucinous ovarian cancers, with strong staining in about 29%.4Annals of Oncology. HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers About 45% of clear cell cancers stain moderate or strong, but only about 10% strongly.5Annals of Oncology. HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers In high-grade serous cancer, the most common type, about 18% stain moderate or strong and only about 5% strongly.6Annals of Oncology. HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers Extra gene copies follow the same pattern, about 25% in mucinous tumors versus about 3% in serous ones.7PubMed Central. HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies Your tumor type, already on your pathology report, hints at how likely a strong result is, but only testing can tell you your actual score.
The gene is the instruction and the protein is the product, so extra gene copies usually lead to extra protein, but not always. Some tumors make a lot of protein without extra copies. That is why labs sometimes use two kinds of tests, and why a report may list a stain score and a gene result separately.
The HER2 result may appear in the same pathology report or as a later add-on. If you don’t see it, ask your oncologist whether HER2 testing was done.
A HER2 result is only one feature of the tumor, alongside its type, grade, and stage. It adds information about drug options and doesn’t replace the rest of the report.
How HER2 Testing Works and What Your Score Means
The first test is a stain on a slice of your tumor tissue, listed on reports as IHC, or immunohistochemistry. A pathologist grades how strongly the cell surfaces color: 0, 1+, 2+, or 3+. Scores of 0 and 1+ mean little or faint staining, while 3+ means strong staining that wraps around the cell edge. Guidelines treat 3+ as HER2-positive across gynecologic cancers.8HER2Know. HER2-Positive Ovarian Cancer: Diagnosis and Treatment Results of 0 and 1+ reliably match the gene test, and so do 3+ results.9PubMed Central. HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
A 2+ score is called equivocal, meaning unclear.10PubMed Central. HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients Only about 1 in 4 ovarian tumors scoring 2+ actually turn out to have extra HER2 gene copies,11PubMed Central. HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients so labs often confirm 2+ with FISH, a test that counts HER2 gene copies under a microscope.12PubMed Central. HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients This stain-then-gene-test approach is the same one used in breast cancer, and it works for ovarian cancer.13PubMed Central. HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients In mucinous ovarian cancer, clear stain results agreed with the gene test about 98% of the time.14PubMed. HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer
On newer reports you may see the term HER2-low. It describes 1+ or 2+ results without extra gene copies. Some newer drugs work at these lower levels, so low isn’t automatically nothing. Ask whether your exact score qualifies for any current drug or trial.
Testing usually uses tissue already removed at surgery or biopsy, so no new procedure is needed. Results can take one to two weeks, longer if a gene test is added. Ask for the actual numeric score, not just “positive” or “negative.”
A biopsy only reflects the piece of tumor it came from.15PubMed Central. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles In one serous cancer, HER2 gene status differed between regions of the same tumor,16PubMed Central. Intratumoral Genomic Heterogeneity May Hinder Precision Medicine Strategies in Patients with Serous Ovarian Carcinoma so a sample from a single spot could miss HER2 that is present elsewhere.17PubMed Central. Intratumoral Genomic Heterogeneity May Hinder Precision Medicine Strategies in Patients with Serous Ovarian Carcinoma In one small study, cells from abdominal fluid were HER2-positive even when the original tumor tissue stained negative.18Cancer Research. Overexpression of HER-2 in Ovarian Carcinomas If you have new tissue from a recurrence, asking whether it can be retested is reasonable.
Does HER2 Change Your Outlook
Across many studies, women whose ovarian cancers expressed HER2 had shorter overall survival on average.19PubMed Central. The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies They also tended to see their cancer return or grow sooner.20PubMed Central. The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies Tumors scoring 2+ or 3+ were tied to poorer survival, especially in high-grade serous cancers with a DNA-repair weakness, which reports list as HRD.21PubMed. Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression These figures come mostly from before the newest HER2 drugs, which may change the picture. This is an association seen in groups of patients, and it doesn’t prove HER2 itself causes the poorer outcomes.
These statistics describe groups, not what will happen to you. Stage, tumor type, and response to earlier treatment matter a great deal. A positive result also means a target exists, which is a reason for hope as well as concern.
HRD means the tumor has trouble repairing certain kinds of DNA damage, which can make it respond to platinum chemotherapy and PARP inhibitors. Since the link between HER2 and poorer survival was seen especially in this group, HRD status may be worth discussing along with the HER2 score. Your report may list HRD separately, often alongside BRCA results, and your oncologist can explain how the two fit together.
Treatments That Target HER2
Trastuzumab deruxtecan (T-DXd, brand name Enhertu) is an antibody that latches onto HER2 while carrying a chemo payload.22PubMed. Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets The antibody attaches to HER2 on the cell surface, and the cell then draws the drug inside. Once inside, the payload is released and damages the cell’s DNA, which kills it. Because of this, more of the chemo goes to cells that display HER2 than with ordinary chemotherapy.
In a key trial of HER2-expressing tumors, it shrank tumors in about 45% of women with ovarian cancer.23PubMed Central. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial Those women had already received other treatments, and safety matched what was known from other cancers.24PubMed Central. Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses Guidelines recognize HER2 3+ as a reason to consider this kind of therapy, and stain results for HER2 are a recognized guide for these drugs.25HER2Know. HER2-Positive Ovarian Cancer: Diagnosis and Treatment26PubMed. Predictive Biomarker Tests for Ovarian Cancer: A Primer for Pathologists
That 45% needs careful reading. Shrinking tumors is different from curing the cancer, and shrinkage doesn’t always last. The ovarian number also comes from a smaller set of women within a trial of many tumor types.
T-DXd is given as an IV infusion, typically every three weeks. It is usually offered after other treatments, often for recurrent disease, and continues as long as it works and side effects are manageable.
Earlier HER2 drugs had more modest results. Pertuzumab, an antibody that blocks HER2, was added to gemcitabine chemo in platinum-resistant ovarian cancer.27PubMed. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer Tumors shrank in about 14% of women versus about 5% with chemo alone,28PubMed. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer but the delay in cancer growth wasn’t clearly proven.29PubMed. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
Other treatments are still being studied. Disitamab vedotin, another targeted chemo drug, held steady drug levels at the tumor for about a week in laboratory models.30PubMed Central. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy Some targeted chemo drugs can also kill nearby low-HER2 cells in lab tests, which may help tumors with patchy HER2.31PubMed Central. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Promising Antitumor Activity in Epithelial Ovarian Carcinoma with HER2/Neu Expression Neratinib, a HER2-blocking pill, slowed HER2-heavy ovarian cancer cells in the lab.32PubMed Central. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo Immune approaches, such as engineered T cells and combinations with immunotherapy, have shown promise in lab studies but aren’t standard care.33PubMed Central. Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors34PubMed Central. Enhancing ovarian cancer treatment by synergistically targeting HER2 and PD-L1
Many HER2 drugs are available only through clinical trials, and your HER2 score often decides eligibility. Ask your oncologist, or search ClinicalTrials.gov for “HER2 ovarian.”
Why Treatment Sometimes Stops Working
Understanding resistance is a main focus of HER2 research in gynecologic cancers.35PubMed. Targeting HER2 in ovarian and uterine cancers: challenges and future directions Resistance means the cancer cells find a way to keep growing even though the drug is still present. It can be there from the start, so a drug never works, or it can develop after a good response that later fades.
In lab studies, ovarian cancer cells resisted HER2 antibodies by boosting their internal antioxidant defenses.36PubMed Central. A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells Cells resisted immune-based HER2 treatments by shutting down a signal that helps T cells kill them.37PubMed Central. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation Researchers are therefore testing combinations, such as HER2 plus blood-vessel-blocking drugs, to cut off escape routes.38PubMed Central. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer
If a HER2 drug stops working, scans will show growth and your team will discuss next options. Other chemotherapies or a different targeted drug may still help, and retesting new tissue may reveal changes worth knowing.
Side Effects to Watch For
Common side effects include low blood counts, tiredness, hair loss, nausea and vomiting, and muscle and joint pain.39American Cancer Society. Targeted Therapy for Ovarian Cancer Rare but serious effects include changes in heart function and very low white cell counts that raise infection risk.40American Cancer Society. Targeted Therapy for Ovarian Cancer Nausea and tiredness often show up in the days after an infusion and may ease before the next one. Low blood counts usually reach their lowest point between doses, which is why blood tests are scheduled regularly. Many effects can be eased with medicines or schedule changes, so tell your team instead of enduring them.
Heart muscle cells also carry HER2, so drugs that target it can weaken the heart’s pumping.41PubMed Central. Adverse events of targeted therapies approved for women’s cancers The usual sign is a drop in the share of blood the heart pumps out with each beat, often without symptoms.42PubMed Central. Adverse events of targeted therapies approved for women’s cancers Caught early, this is reversible most of the time.43PubMed Central. Adverse events of targeted therapies approved for women’s cancers Expect regular heart scans during treatment.
T-DXd can also cause lung inflammation that needs prompt treatment. A new cough, shortness of breath, or fever should be reported right away, and your team may pause treatment while checking. Also call your care team for fever or chills, which can signal infection, for swelling, breathlessness on lying down, or a racing heartbeat, and for vomiting that prevents keeping fluids down.
Questions to Ask Your Oncologist
HER2 testing is recommended for all patients with recurrent ovarian cancer.44HER2Know. HER2-Positive Ovarian Cancer: Diagnosis and Treatment If your cancer has come back and HER2 hasn’t been checked, ask about it. A borderline 2+ result without a gene test is also worth following up.
Questions worth bringing:
- Was my tumor tested for HER2, and what was the score?
- Was a gene test done if the score was 2+?
- Am I eligible for T-DXd or a HER2 trial?
- Could tissue from a recurrence be retested?
- How will my heart and lungs be monitored?
Bring a copy of your pathology report so you and your oncologist can look at the same numbers.
Second opinions are routine and won’t offend your doctor. Large cancer centers may offer more HER2 trials, and you can request that your slides be reviewed elsewhere.